AUTOMA+ 2025 gathers leading pharmaceutical and biotechnology professionals from across the globe on 24–25 November in Vösendorf, Austria to exchange insights, build partnerships and advance the development of medicines. While the Congress places particular emphasis on Europe, active participation from other regions broadens its perspective and enriches the exchange of ideas.
Among the distinguished European participants are several of Spain’s foremost pharmaceutical organisations. RidNova Pharmaceuticals, an innovative contract development and manufacturing company based in Barcelona, provides comprehensive pharmaceutical services across multiple therapeutic areas. Esteve, a prominent Spanish group specialising in pain management and chronic diseases, and LETI Pharma, an international pharmaceutical company focused on health and wellness, also join the AUTOMA+ 2025.
From Portugal, Generis Farmacêutica S.A. stands out as one of the country’s leading generics manufacturers, recognised for its high production standards and sustainable operations that serve both European and international markets. The United Kingdom contributes scientific leadership through the International Agency for Research on Cancer (IARC), part of the World Health Organisation, globally known for its collaborative work in cancer research and prevention.
Eastern Europe are represented by the Bulgarian office of Astellas Pharma. This Japanese company brings a research-driven, patient-centred approach to innovation. Peptide Dynamics LLC, a Swiss-American company bridging cutting-edge biotechnology services with investment opportunities in pioneering peptide research and development, also participates at the Congress. Moreover, Venus Remedies Limited, headquartered in Panchkula, India, adds extensive analytical expertise and a growing international presence, underscoring the truly global dimension of the Congress.
Together, these organisations and a wider European contingent of industry leaders reaffirm AUTOMA+ 2025 as a key platform for collaboration, innovation and strategic dialogue across pharma. The two-day agenda features discussions, case studies and sessions that foster partnerships and explore forward-looking approaches to improve safety, efficiency and intelligence in pharmaceutical operations.
Be part of the conversation shaping the future of smart pharma with AUTOMA+ 2025: https://sh.bgs.group/3i4
